Program
fitusiran
Also written as “Fitusiran”, “Fitusiran (SAR439774)” and “ALN-AT3SC”.
Its studies are mostly in Hemophilia A, led by Sanofi.
Furthest: phase 4, since Nov 17, 202310 company-led studies, 3 open or runningNext primary completion: Mar 25, 2027 (phase 3)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanofi | 103 open or running | phase 4since Nov 17, 2023 | Jan 13, 2014 | Mar 25, 2027phase 3 · NCT05662319 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 13, 2014First study: phase 1 study in Hemophilia AFirst studyNCT02035605 · 51 enrolled · United States, Bulgaria, Russian Federation and more
- Sep 15, 2015Phase 2 study in Hemophilia ANCT02554773 · 34 enrolled · United States, Bulgaria, Russian Federation and more
- Jan 25, 20182 phase 3 studies in Hemophilia ANCT03417245, NCT03417102
- May 25, 2018Phase 3 study in Hemophilia ANCT03549871 · 80 enrolled · United States, Australia, China and more
- Nov 25, 2018Phase 3 study in Hemophilia ANCT03754790 · 281 enrolled · United States, Australia, Canada and more
- Jun 3, 2019Phase 3 study in Hemophilia ANCT03974113 · 32 enrolled · United States, Canada, India and more
- Dec 14, 2022Phase 3 study in Hemophilia ANCT05662319 · 91 enrolled · United States, Canada, China and more
- Nov 17, 2023Phase 4 study in Hemophilia ANCT06145373 · 20 planned · United States, Taiwan
- Dec 9, 2025Phase 3 study in Hemophilia ANCT07285460 · 85 planned · United States, Belgium, Brazil and more
Ahead
- Mar 25, 2027Primary completion: phase 3 study in Hemophilia ANCT05662319
- May 28, 2028Primary completion: phase 4 study in Hemophilia ANCT06145373
- Aug 4, 2029Primary completion: phase 3 study in Hemophilia ANCT07285460
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07285460Hemophilia A · United States, Belgium, Brazil and more | 3 | Recruiting | Aug 4, 2029 | 85 |
| NCT06145373Hemophilia A · United States, Taiwan | 4 | Recruiting | May 28, 2028 | 20 |
| NCT05662319Hemophilia A · United States, Canada, China and more | 3 | Active, not recruiting | Mar 25, 2027 | 91 |
| NCT03974113Hemophilia A · United States, Canada, India and more | 3 | Completed | Aug 4, 2026 | 32 |
| NCT03754790Hemophilia A · United States, Australia, Canada and more | 3 | Completed | Sep 14, 2026 | 281 |
| NCT03549871Hemophilia A · United States, Australia, China and more | 3 | Completed | Jan 20, 2022 | 80 |
| NCT03417245Hemophilia A · United States, Australia, China and more | 3 | Completed | Jan 26, 2021 | 120 |
| NCT03417102Hemophilia A · United States, Australia, Canada and more | 3 | Completed | Nov 25, 2020 | 60 |
| NCT02554773Hemophilia A · United States, Bulgaria, Russian Federation and more | 2 | Completed | Mar 21, 2023 | 34 |
| NCT02035605Hemophilia A · United States, Bulgaria, Russian Federation and more | 1 | Completed | Jul 20, 2017 | 51 |
How it is read
Names in the registry
- “Fitusiran”, 5 entries
- “Fitusiran (SAR439774)”, 2 entries
- “fitusiran”, 2 entries
- “ALN-AT3SC”, 1 entry
Conditions, from the studies’ own filings
- Hemophilia A, 10 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.